期刊
HUMAN IMMUNOLOGY
卷 61, 期 7, 页码 640-650出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/S0198-8859(00)00126-9
关键词
rheumatoid arthritis; synthetic peptides; antigen presentation; HLA-DR molecules
类别
资金
- NCI NIH HHS [R35-CA 47554] Funding Source: Medline
- NIAID NIH HHS [N01-AI 45198] Funding Source: Medline
Copolymer 1 [Cop 1, poly (Y, E, A, K)] is a random synthetic amino acid copolymer effective in the treatment of relapsing forms of multiple sclerosis (MS), a disease chat is linked to HLA-DR2 (DRB1*1501). Another copolymer [poly (Y, A, K)1 was also identified thar binds to rheumatoid arthritis (RA)-associated HLA-DR1 (DRB1*0101) or HLA-DR4 (DRB1*0401) molecules and inhibits the response of HLA-DR1- and -DR4-restricted T cell clones to an immunodominant epitope of collagen type II (CII) 261-273 (a candidate autoantigen in RA). In the present: study various peptides have been synthesized based on binding motifs of Cop 1 for HLA-DR1 and -DR4 molecules. Those peptides with K at P-1 or K at P8 were particularly effective as inhibitors of binding of CII 261-273, of Cop 1 and of the influenza virus hemagglutinin peptide 306-318 to these class II proteins. Moreover, several of them were also potent inhibitors of the CII 261-273-reactive T cell clones. These Findings suggest that small peptides or their more stable derivatives may be able to substitute for copolymers in the treatment of RA, and by implication of MS. Human Immunology 61, 640-650 (2000). (C) American Society for Histocompatibility and Immunogenetics, 2000. Published by Elsevier Science Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据